A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
AbstractBackground. The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antit
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
21 February 2016
|
| In: |
Neuro-Oncology
Year: 2016, Volume: 18, Issue: 8, Pages: 1146-1156 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/now009 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/neuonc/now009 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/18/8/1146/1751761 
|
| Author Notes: | Alba A. Brandes, Antoine F. Carpentier, Santosh Kesari, Juan M. Sepulveda-Sanchez, Helen R. Wheeler, Olivier Chinot, Lawrence Cher, Joachim P. Steinbach, David Capper, Pol Specenier, Jordi Rodon, Ann Cleverly, Claire Smith, Ivelina Gueorguieva, Colin Miles, Susan C. Guba, Durisala Desaiah, Michael M. Lahn, and Wolfgang Wick |
| Summary: | AbstractBackground. The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antit |
|---|---|
| Item Description: | Gesehen am 16.10.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/now009 |